2025-01-21 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Investment Review

**1. Performance Comparison & Divergence:**

Intuitive Surgical Inc. (ISRG) is a company that manufactures and sells da Vinci surgical systems and related instruments and accessories.

The cumulative return of ISRG is 332.21%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 118.37%.  The difference in cumulative returns is 213.8%.  The provided relative divergence of 100% indicates ISRG's performance is at the highest point within its historical range relative to the S&P 500.  This highlights a substantial outperformance.  The alpha consistently shows 0.0 across all provided periods, suggesting performance largely aligns with market beta, while the extremely high Beta across the provided years indicates extreme sensitivity to market movements.

**2. Recent Price Movement:**

* **Closing Price:** $592.64
* **5-Day Moving Average:** $567.09
* **20-Day Moving Average:** $541.11
* **60-Day Moving Average:** $534.91

The price is currently above all three moving averages, suggesting a short-term uptrend.  The recent price change of $1.47 reflects a slight increase.

**3. Technical Indicators & Expected Return:**

* **RSI:** 71.40 - This indicates the stock is approaching overbought territory.
* **PPO:** 1.13 - A positive PPO suggests bullish momentum.
* **20-Day Relative Divergence Change:** +0.7 -  Confirms the short-term uptrend.

The recent price increase is relatively moderate, not signifying a dramatic spike.  The expected return of 16.6% over the long term (2+ years) represents a significant outperformance compared to the S&P 500, reflecting the potential for continued strong growth.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|---------------|
| 2024-10-18 | $1.59  | $2.04 Billion |
| 2024-07-19 | $1.48  | $2.01 Billion |
| 2024-04-19 | $1.54  | $1.89 Billion |
| 2023-10-20 | $1.18  | $1.74 Billion |
| 2023-10-18 | $1.18  | $1.74 Billion | *(Duplicate entry, likely a data error)*

Earnings show consistent revenue growth with some fluctuation in EPS.  The duplicate entry should be investigated for accuracy.  Overall, the trend suggests healthy financial performance.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-09-30 | $2.04B    | 67.41%        |
| 2024-06-30 | $2.01B    | 68.30%        |
| 2024-03-31 | $1.89B    | 65.87%        |
| 2023-12-31 | $1.93B    | 66.24%        |
| 2023-09-30 | $1.74B    | 66.94%        |

Revenue shows a generally upward trend, although some quarterly fluctuations are evident. Profit margins remain high and relatively stable, showcasing the company's strong profitability.


**Capital and Profitability:**

| Quarter | Equity     | ROE      |
|---------|------------|----------|
| 2024-09-30 | $15.58B   | 3.63%    |
| 2024-06-30 | $14.71B   | 3.58%    |
| 2024-03-31 | $13.96B   | 3.90%    |
| 2023-12-31 | $13.31B   | 4.56%    |
| 2023-09-30 | $12.54B   | 3.32%    |

Equity is steadily increasing, indicating strong financial health. ROE shows some fluctuation but generally remains positive, highlighting the efficiency of capital utilization.


**7. Overall Analysis:**

ISRG demonstrates strong historical and recent performance, significantly outperforming the S&P 500.  Financial statements reveal healthy revenue growth, high profit margins, and increasing equity. While the RSI suggests a potential near-term correction, the positive PPO and upward price trend signal continued bullish momentum. The projected long-term return significantly exceeds the S&P 500, making it an attractive investment for long-term growth. However, investors should be mindful of the high beta which implies significant market risk.  Further investigation into the duplicate earnings data entry is recommended.
